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ABSTRACT
Epilepsy is a complex brain disorder with diverse clinical features. Moreover, epilepsy is one of the most 
common serious neurological disorders worldwide with no age, racial, social class, national or geographic 
boundaries. This disease causes recurring seizures that happen when clusters of neurons in the brain send 
out wrong signals. A common way to explain seizures is that a disruption has ocurred in the normal balan-
ce of excitation and inhibition. Using different experimental models, it is clear that genes, developmental 
mechanisms, and neural plasticity play major roles in creating a state of underlying hyperexitability. Epilep-
sy patients may have strange sensations and emotions or behave strangely before a seizure occurs. Diffe-
rent features of epileptic seizures have been reported, where the patients may have violent muscle spasms 
or lose consciousness. This is a disorder with many possible causes, making mechanistic predictions a 
challenge. Anything that disturbs the normal pattern of neuron activity - from illness to brain damage to 
abnormal brain development - can lead to epilepsy. Several experimental models have been developed wi-
th the objective to gain insight into the mechanisms of disruption involved in epilepsy. Nonetheless, the 
target and/or mechanism of action of many of drugs used to control epilepsy remains unclear. Their eluci-
dation should improve diagnosis and may provide new targets for the development of speciﬁ c prophylactic 
therapies for epilepsy.
Key words
epilepsy, seizures, mechanims, treatment.
RESUMO
A epilepsia é desordem cerebral complexa com diversas manifestações clínicas. Além disso, a epilepsia 
é uma das doenças neurológicas mais comuns ao longo do planeta, sem barreiras geográﬁ cas para idade, 
raça, sexo ou nacionalidade. A doença causa convulsões recorrentes que ocorrem quando grupos de neu-
rônios cerebrais sinalizam erroneamente. Um modo comum de explicar as convulsões é a de que houve 
uma falha do balanço normal de excitação e inibição. Através do uso de diferentes modelos experimentais 
está claro que genes, mecanismos de desenvolvimento e plasticidade neural têm um papel importante em 
criar o estado de hiperexcitabilidade. Pacientes com epilepsia podem ter sensações estranhas e se com-
portar de forma estranha antes de uma convulsão. Diferentes formas de convulsões epilépticas são docu-
* Rede Metodista de Educação do Sul, Centro Universitário Metodista IPA, Porto Alegre, RS, Brazil.
** Department of Genetics and Moleclar Biology, Centro de Investigacion y de Estudios Avanzados (Cinvestav-IPN), Me-
xico City, México.
*** Instituto de Investigaciones Bioquimicas de Bahia Blanca (INIBIBB), Bahia Blanca, Argentina.
**** Institute of Neuroscience, Carleton University, Ottawa, Canada.
Ciencia_em_Movimento_18.indd   39 10/12/2007   10:57:00
Ciência em Movimento   |   Ano IX   |   Nº 18   |   2007/2 
40
Past, present and future of epilepsy
mentadas, onde os pacientes podem ter violentos espasmos musculares ou perda de consciência. Esta é 
uma doença com várias causas possíveis, fazendo com que a previsão dos mecanismos seja um desaﬁ o. 
Qualquer modiﬁ cação no padrão normal de atividade neuronal, desde doenças, dano cerebral até desenvol-
vimento cerebral anormal, pode levar a epilepsia.  Diversos modelos experimentais têm sido desenvolvidos 
com o objetivo de entender os mecanismos envolvidos na epilepsia. Entretanto, o alvo ou o mecanismo de 
ação de muitos dos fármacos utilizados no controle da epilepsia permanecem obscuros. A sua elucidação 
deverá melhorar o diagnóstico e providenciar novos alvos para o desenvolvimento de terapias proﬁ láticas 
para a epilepsia.
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1. GENERAL FEATURES
Epilepsy is a brain disorder characterized predomi-
nantly by recurrent and unpredictable interruptions of 
normal brain function, called epileptic seizures. Epi-
lepsy is not a singular disease entity but a variety of 
disorders reﬂ ecting underlying brain dysfunction that 
may result from many different causes (FISHER et al., 
2005). This disorder is one of the most common neu-
rologic problems worldwide. Approximately 2 million 
persons in the United States have epilepsy, and 3 per-
cent of persons in the general population will have 
epilepsy at some point in their lives (ANNEGERS, 
2001). In recent years, important advances have been 
made in the diagnosis and treatment of seizure disor-
ders. However, the cellular and molecular mechanis-
ms by which epilepsy develops, called epileptogene-
sis, is still unknown (SCHACHTER, 2001; CHANG and 
LOWESTEIN, 2003).
In patients with epilepsy, the normal pattern of 
neuronal activity becomes disturbed, causing strange 
sensations, emotions, behavior or sometimes convul-
sions, muscle spasms, and loss of consciousness. 
Anything that disturbs the normal pattern of neuron 
activity can lead to seizures. Despite advances in the 
sensitivity of diagnostic tests less than half of the pa-
tients with this disorder have an identiﬁ able cause, 
such as congenital brain malformations, inborn errors 
of metabolism, brain trauma, brain tumors, stoke, in-
tracranial infection, vascular malformation, cerebal 
degeneration, withdraw states, and iatrogenic drug 
reactions (SCHACHTER, 1998; SCHACHTER, 2004). 
Cerebral disease, cerebral degeneration and brain tu-
mors are more common causes in elderly patients 
than in younger patients (SCHOLD et al., 1977).
An epileptic seizure is deﬁ ned as a transient oc-
currence of signs and/or symptoms due to abnormal 
excessive or synchronous neuronal activity in the 
brain. Seizures can last from a few seconds to a few 
minutes. They can have many symptoms, from con-
vulsions and loss of consciousness to blank staring, 
lip smacking, or jerking movements of arms and legs 
(FISHER et al., 2005). This is a clinical event; therefore, 
detailed speciﬁ cation of these clinical phenomena du-
ring an epileptic seizure is difﬁ cult, because of the 
wide range of possible manifestations. Seizure pre-
sentation depends on location of onset in the brain, 
patterns of propagation, maturity of the brain, con-
founding disease processes, sleep–wake cycle, me-
dications, and a variety of other factors. Seizures can 
affect sensory, motor, and autonomic function; cons-
ciousness; emotional state; memory; cognition; or 
behavior. Not all seizures affect all of these factors, 
but all inﬂ uence at least one. In this context, sensory 
manifestations are taken to include somatosensory, 
auditory, visual, olfactory, gustatory, and vestibular 
senses, and also more complex internal sensations 
consisting of complex perceptual distortions (Com-
mission on epidemiology and prognosis, International 
League Against Epilepsy, 1993; BROWNE, 1999, 
WHO, 2006). 
According to the 2001 ILAE Glossary of Descripti-
ve Terminology for Ictal Semiology (BLUME et al., 
2001), cognitive deﬁ cits during seizures can appear as 
problems with perception, attention, emotion, me-
mory, execution, praxis, or speech. Memory distor-
tions can be either negative or positive, in the sense 
of interruption of memory formation or retrieval as a 
negative symptom, or intrusion of inappropriate me-
mories as a positive symptom. Positive memory 
symptoms give rise to “d´ej`a vu” and other forced 
memories during seizures. Some of the distorted me-
mories previously were classiﬁ ed as psychic symp-
toms, which is a potentially ambiguous term. Emotio-
nal state is difﬁ cult to specify but must be considered 
in the deﬁ nition, because some seizures manifest as 
fear, elation, satisfaction, anxiety, or other subjective 
sensations that cannot be ascribed to the primary sen-
ses (FISHER et al., 2005). 
Epilepsy is among the disorders that are strongly 
associated with signiﬁ cant psychological and social 
consequences for everyday living (BAKER, 2002). Pe-
ople with hidden disabilities such as epilepsy are 
among the most vulnerable in any society. While their 
vulnerability may be partly attributed to the disorder 
itself, the particular stigma associated with epilepsy 
brings a susceptibility of its own. Stigmatization leads 
to discrimination, and people with epilepsy experience 
prejudicial and discriminatory behaviour in many sphe-
res of life and across many cultures (PAHL and BOER, 
2005). People with epilepsy experience violations and 
restrictions of both their civil and human rights. Civil 
rights violations, such as unequal access to health and 
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life insurance or prejudicial weighting of health insu-
rance provisions, withholding of the right to obtain a 
driving licence, limitations to the right to enter particu-
lar occupations and the right to enter into certain legal 
agreements, in some parts of the world even marriage, 
are severely aggravated by epilepsy. Discrimination 
against people with epilepsy in the workplace and in 
respect of access to education is not uncommon for 
many people affected by the condition (WHO, 2006).
2. SEIZURE TYPES
There are many classiﬁ cations of epilepsy. A full 
classiﬁ cation would be extremely complicated. In ge-
neral, epilepsy syndromes types are based on the 
speciﬁ c biologic mechanisms involved in the seizure 
and parts of the anatomy where the seizure is located. 
The seizure type usually is established from the des-
cription of the behaviors that occure before, during 
and after the seizure. The two main seizure types are 
generalized and partial seizures. Generalized seizures 
affect both sides of the brain simultaneosly and usu-
ally are not associated with cerebral pathology. Partial 
seizures (also called focal or localized) affect a restric-
ted area of the brain and indiacte the possibility of an 
underlying lesion. In some cases, partial seizures can 
spread to wide regions of the brain (SCHACHTER, 
2004; WHO, 2006). 
Although speciﬁ c seizures can be classiﬁ ed accor-
ding to their clinical features, e.g., partial and genera-
lized seizures (Commission on Classiﬁ cation and Ter-
minology of the International League against Epilepsy, 
1981), epilepsy syndromes can also be classiﬁ ed ac-
cording to the type of seizure (Table 1), the presence 
or absence of neurologic or developmental abnorma-
lities, and electroencephalographic (EEG) findings 
(Commission on Classiﬁ cation and Terminology of the 
International League against Epilepsy, 1989; LÖS-
CHER, 1993).
2.1. Partial seizures
This is the more common type of epilepsy and is 
generally deﬁ ned as a disorder of the neurons that 
starts on one side of the brain. It is currently subcate-
gorized as “simple”, “complex partial” and “seconda-
rily generalised” seizures. The term “partial” however, 
implies that such seizures affect only small or speciﬁ c 
locations in the brain. In reality, they almost always 
involve diffuse and even widespread problems. (i) Sim-
ple Partial Seizures. A person with a simple partial sei-
zure does not lose consciousness but may experience 
confusion, jerking movements, tingling, or odd mental 
and emotional events. Such events may include “d´ej`a 
vu”, mild hallucinations, or extreme responses to smell 
and taste. After the seizure, the patient usually has 
temporary weakness in certain muscles. (ii) Complex 
Partial Seizures. Slightly over half of the seizures in 
adults are complex partial types, and about 80% of 
these seizures originate in the temporal lobe, the part 
of the brain located close to the ear. Disturbances the-
re can result in loss of judgment, involuntary or uncon-
trolled behavior, and a loss of consciousness. About 
20% of these patients have seizures that start in the 
brain’s frontal lobes. Prior to the actual seizure, people 
sometimes experience a warning sign, known as an 
aura, which can be an odd odor, a feeling of warmth, 
or a visual or auditory hallucination. They then may 
lose consciousness brieﬂ y and appear to others as 
motionless with a vacant stare. Emotions can be exa-
ggerated; some sufferers even appear to be drunk. 
After a few seconds, some may begin to perform re-
petitive movements, such as chewing or smacking of 
lips. Episodes usually last no more than two minutes, 
and people can have them infrequently or as often as 
every day or more. A throbbing headache may follow 
a complex partial seizure. (iii) Partial seizures becoming 
secondarily generalised. In these, partial seizures end 
with the person having a motor convulsion (MOSEWI-
CK and SO, 1996; BROWNE and HOLMES, 1999; 
SCHACHTNER, 2004; ENGEL, 2006; SEINO, 2006 ). 
Table 1 - Epilepsy Seizures
PARTIAL GENERALIZED
Focal Local Absence
Simple Myoclonic
Complex Clonic
Partial Tonic
evolving to secondarily Tonic-clonic
Generalized Atonic
Table 1. Classiﬁ cation of epileptic seizures. Seizures are 
mainly divided into partial and generalized. Partial seizures 
are charachterized by clinical or EEG evidence that suggest 
a localization of the attacks in the brain, while generalized 
seizure lack localization.
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2. 2. Generalized seizures
This type of seizure is caused by nerve cell distur-
bances that occur in more diffuse areas of the brain 
than do partial seizures. Therefore, they have a more 
serious effect on the patient. They are further subca-
tegorized as tonic−clonic (or grand mal) or absence 
(petit mal) seizures. (i) Tonic−Clonic (Grand Mal) Sei-
zures. The ﬁ rst stage of a grand mal seizure is called 
the tonic phase, in which the ﬂ exor and extensor mus-
cles suddenly contract, causing the patient to fall and 
lie rigidly for about 10 to 30 seconds. Some people 
experience a premonition or aura before a grand mal 
seizure; most, however, lose consciousness without 
warning. If the throat or larynx is affected, there may 
be a high−pitched musical sound called stridor when 
the patient inhales. Spasms occur for about 30 secon-
ds to a minute as the seizure enters the clonic phase, 
when the muscles begin to alternate between relaxa-
tion and rigidity. After this phase, the patient may lose 
bowel or urinary control. The seizure usually lasts a 
total of two to three minutes, after which the patient 
remains unconscious for a while and then awakens to 
confusion and extreme fatigue. A severe throbbing 
headache similar to migraine may also follow the 
tonic−clonic phases. (ii) Absence (Petit Mal) Seizures. 
Petit mal or absence seizures are brief (three to 30 
seconds) with losses of consciousness and may con-
sist of only a short cessation of physical movement 
and loss of attention. Such seizures may pass unnoti-
ced by others. Small children may simply appear to be 
staring or walking distractedly. Petit mal may be con-
fused with simple or complex partial seizures or even 
with attention deﬁ cit disorder. In petit mal, however, 
a person may experience attacks as often as 50 to 100 
times a day. About 25% of patients with petit mal 
develop grand mal seizures. An EEG test that shows 
a speciﬁ c brain wave pattern can usually identify the-
se patients (MOSEWICK and SO, 1996; BERKOVIC, 
1997; BROWNE and HOLMES, 1999; SCHACHTNER, 
2004; ENGEL, 2006; SEINO, 2006 ). 
3. CELLULAR AND MOLECULAR MECHANISMS
3.1. Voltage-gated ion channels
The discovery of genetically determined epileptic 
syndromes associated with speciﬁ c mutations of ge-
nes codifying for subunits of voltage or ligand-activa-
ted ion channels highlights the role of ion channels in 
epileptogenesis. Furthermore some forms of epilepsy 
might be caused by alterations in ion channels that 
lead to a reduced repolarization reserve or that incre-
ase or prolong excitation. Voltage-gated ion channels 
clearly are involved in the pathogenesis of epilepsy, 
with evidence implicating derangement of sodium 
(Na+), potassium (K+), and calcium (Ca2+) voltage-ga-
ted channels, in both inherited and acquired forms of 
epilepsy (STEINLEIN and NOEBELS, 2001).
Neuronal firing is controlled by numerous ionic 
conductances that interact to produce a wide array of 
threshold and subthreshold behaviors. The foundation 
of the understanding of neuronal ﬁ ring comes from 
the pioneering work of Hodgkin and Huxley, who sho-
wed that the action potential upstroke is due to the 
rapid inﬂ ux of sodium ions (Na+). Na+ inﬂ ux through 
speciﬁ c ion channels in the neuronal membrane cau-
ses a depolarizing inward current. Once open, Na+ 
channels inactivate and cannot pass further current 
until they recover from inactivation. Na+ channel inac-
tivation, in conjunction with outward current through 
potassium (K+) channels, allows the membrane poten-
tial to repolarize to the resting level.  Alterations of Na+ 
currents can lead to abnormal neuronal activity, such 
as occurs in epilepsy. The transient voltage-gated Na+ 
current mediates the upstroke of the action potential. 
A small fraction of Na+ current, termed the persistent 
Na+current , fails to inactivate signiﬁ cantly, even with 
prolonged depolarization (STAFSTRON, 2007). Fur-
thermore, the generalized epilepsy with febrile seizu-
res plus (GEFS+) has been associated with mutations 
in the Na+ channel β-subunit gene, SCN1B (GEFS+1), 
and the Na+ channel α-subunit gene SCN1A (GE-
FS+2). These mutations might decrease the rate of 
Na+ channel inactivation, resulting in different epilep-
sies  (SINGH, et al., 1999, ESCAYG, et. al., 2000).
Potassium channels are important regulators of 
electrical signaling and are implicated in the pathology 
of epilepsy (for a review see ROGAWSKI, 2000). The-
re have been described two proteins related to the 
benign familial neonatal convulsions (BFNC), a gene-
ralized epilepsy syndrome. Generalized epilepsies of-
ten have a strong genetic component. In 1998 two 
homologous voltage-activated K+ channels designa-
ted KCNQ2 (KvEBN1) and KCNQ3 (KvEBN2) were 
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identiﬁ ed as the disease genes in BFNC (BIERVERT 
et al., 1998; SINGH et al., 1998, CHARLIER et al., 
1998). KCNQ2 and KCNQ3 encode proteins with se-
quence homology to members of the six-transmem-
brane domain K+ channel gene superfamily. Although 
KCNQ2 and KCNQ3 can each form functional voltage-
dependent K+ channels by themselves, evidence indi-
cates that the two subunits coassemble to form he-
teromers. Schroeder and colleagues predicted a 25% 
loss of heteromeric KCNQ2/KCNQ3-channel function 
is sufficient to cause electrical hyperexcitability in 
BFNC (SCHROEDER, et al., 1998). Besides KCNQ2 
and KCNQ3 are expressed in an overlapping distribu-
tion in brain, with high levels in critical areas for seizu-
res, including the hippocampus, neocortex and thala-
mus, but are not expressed in most other tissues. 
Even more, the co-injection of KCNQ2 and KCNQ3 
subunit cRNAs in Xenopus oocytes yields currents 
that are much larger in amplitude (> tenfold) than tho-
se obtained with either of the subunits alone the 
(SCHROEDER et al., 1998; TINEL et al., 1998; YANG 
et al., 1998). 
The  voltage-gated Ca2+ channels play essential 
roles in the nervous system as they are involved in 
neurotransmitter release, gene expression, in the ge-
neration of absence seizures, and their mutations are 
a substrate for juvenile myoclonic epilepsy (ARMIJO 
et al., 2005, CARAFOLI, 2002, WEST et al., 2001). 
Moreover Schumacher et al. (1998) showed that mo-
dulation of postsynaptic Ca2+ channels can contribute 
to the anticonvulsant action of  phenytoin in human 
hippocampal granule cells.
Insight into the structure and function of these 
brain speciﬁ c Na+, K+ and Ca2+ channels will improve 
diagnosis and may provide new targets for the deve-
lopment of speciﬁ c prophylactic therapy for episodic 
cerebral disorders such as epilepsy, and may also be 
important for the study of (neuronal) cell death.
3.2. Neurotransmitters
Epilepsy may also develop because of an abnor-
mality in brain wiring, an imbalance of nerve signaling 
chemicals called neurotransmitters, or some combi-
nation of these factors. The two main neurotransmit-
ters that play a key role in the development and main-
tenance of epilepsy are γ-amino butyric acid (GABA) 
and glutamate (Glu). During neurotransmission both 
amino acid regulate strength and duration of the com-
munication between neurons. Glu “turns on” while 
GABA “turns off” neurotransmission. Besides, neuro-
chemical and pharmacological data support the notion 
that Glutamatergic and GABAergic systems are rela-
ted to the beginning, maintenance and end of many 
types of epilepsy (BRADFORD, 1995). 
GABA is the major inhibitory neurotransmitter in 
the mammalian central nervous system (CNS) (RO-
BERTS, 1976). The development of selective agents 
has led to the identiﬁ cation of at least two distinct 
classes of GABA receptors, GABAA and GABAB. They 
differ in their pharmacological, electrophysiological 
and biochemical properties (OLSEN and TOBIN, 1990; 
TILLAKARATNE et al., 1995). In GABAA receptors the 
GABA-binding site is directly responsible of opening 
the Cl– channel. This in turn potentially can excite the 
cell to ﬁ re or to activate Ca2+ entry via voltage-gated 
channels and has been proposed as a physiologically 
relevant event (OLSEN and DELOREY, 1999). GABAB 
receptors are coupled indirectly to K+ channels. When 
activated, these receptors can decrease Ca+2 conduc-
tance and inhibit cAMP production via intracellular 
mechanisms mediated by G proteins.  Activation of 
GABAA receptors result in an increased inhibition of 
the postsynaptic neuron while GABAB receptors can 
mediate both postsynaptic and presynaptic inhibition 
(VELISEK and MARES, 1995).  Presynaptic inhibition 
may occur as a result of GABAB receptors on nerve 
terminals causing a decrease in the inﬂ ux of Ca2+, the-
reby reducing the release of neurotransmitters (OL-
SEN and DELOREY, 1999). 
GABA exerts its primary (fast) effects through 
chloride currents associated with GABAA receptors, it 
either depolarizes or hyperpolarizes the postsynaptic 
neuron, depending on chloride’s electrochemical gra-
dient across the neuronal membrane. There are evi-
dences in the literature that acute and chronic chan-
ges in chloride transporter expression, by reducing or 
even reversing the inhibitory inﬂ uence of GABA, un-
derlie the generation of seizures acutely or the pro-
cess of epileptogenesis (DZHALA et al, 2005; STAFS-
TROM, 2006). 
Another aspect of the changing perspective on 
GABA concerns the key role it plays in the develop-
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ment of neuronal circuits. It is a major excitatory neu-
rotransmitter in the immature brain at a time when 
glutamatergic synaptic connections are beginning to 
mature (Ben Ari, 2002). In the early postnatal period 
in rats, the pairing of depolarizing GABA-mediated res-
ponses with glutamate release at immature excitatory 
synapses that contain only N-methyl-D-aspartate 
(NMDA) receptors relieves their voltage-dependent 
block by magnesium ions. The resulting NMDArecep-
tor-mediated calcium inﬂ ux provides the signal requi-
red for insertion of AMPA-type glutamate receptors 
into the postsynaptic membrane and, therefore, leads 
to their maturation into active synapses. Given this 
crucial role in the development of excitatory synap-
ses, it is likely that the depolarizing action of GABA 
contributes to the particular vulnerability of neonates 
to seizures and epilepsy. This developmental process 
appears to be analogous to the insertion of AMPA 
receptors that occurs during induction of long-term 
potentiation in more mature brain circuits, when glu-
tamate provides the depolarizing signal. Considering 
the importance of long-term potentiation in learning 
and memory functions, disruption of these analogous 
signaling patterns by seizures may have long-lasting 
consequences in patients at a vulnerable age (MA-
THEWS, 2007).
The GABAA receptor is of prime importance in the 
pathogenesis of absence epilepsy because of its 
apparent role in the synchronization and desynchroni-
zation of thalamocortical circuitry. Perturbation of this 
process leads to the generation of absence seizures. 
The oscillatory burst ﬁ ring of thalamocortical circuitry 
is attributed to the ability of neurons located in the 
nucleus reticularis thalami (nRT) to impose their own 
oscillatory behavior on thalamocortical relay neurons 
located in the ventral basalis (VB) of the thalamus. The 
ability of the nRT to switch between oscillatory and 
burst ﬁ ring dictates electroencephelographic (EEG) 
synchronization and desynchronization. The nRT con-
sists of GABAergic neurons that project to the VB, 
providing inhibitory input. Also, GABAergic nRT neu-
rons project onto one another providing intra-nRT inhi-
bition, which decreases input to the VB. The nRT GA-
BAergic neurons receive glutamatergic inputs from 
thalamocortical VB ﬁ bers and also from corticothala-
mic ﬁ bers projecting back from layer VI of the cerebral 
cortex (YEM, 1985; STERIADE at al, 1993; MCCOR-
MICK and BAL, 1997; GUIN-TING WONG and CAR-
TER SNEAD III, 2001).
The amino acid Glu is considered to be the main 
excitatory neurotransmitter in the mammalian CNS. 
Glu is involved in synaptic plasticity, being essential 
for normal brain function, including memory and lear-
ning (FONUM, 1984; OTTERSEN and STORM-MATHI-
SEN, 1984; COLLINGRIDGE and LESTER, 1989; HE-
ADLEY and GRILLNER, 1990; OZAWA et al., 1998). 
Glu also plays a major role in crucial steps of CNS 
development, participating in synapse induction and 
elimination, cell migration, and differentiation (DAN-
BOLT, 2001). Glu exerts its signaling role by acting on 
glutamate receptors (GluRs) located on the neural cell 
surface in such a way that Glu concentration in the 
surrounding extracellular ﬂ uid usually determines the 
extent of receptor stimulation (OZAWA et al., 1998). 
GluRs are divided in ionotropic and metabotropic 
type. The ﬁ rst ones, as their name indicates, are ion 
permeable receptors (to Na+ and Ca++) and metabo-
tropic receptors are coupled to G proteins and second 
messenger signaling (WATKINS and EVANS, 1981).
The amount of Glu in the synaptic cleft depends 
on the balance between its release by presynaptic 
neurons and its uptake that occurs fundamentally 
through system localized in the astrocyte membrane 
and also in the presynaptic neuronal terminal because 
no extracellular enzyme capable of signiﬁ cantly meta-
bolizing glutamate is known (NICHOLLS, 1993; MA-
RAGASKIS and ROTHSTEIN, 2001). When present at 
high concentrations in the synaptic cleft, Glu may lead 
to excitotoxicity, a process corresponding to oversti-
mulation of Glu receptors leading subsequently to 
neuronal damage (ANDERSON and SWANSON, 
2000; MELDRUM, 2000; DANBOLT, 2001; MARA-
GAKIS and ROTHSTEIN, 2001). Glu toxicity has been 
related to neuronal death in ischemia, hypoxia, hypo-
glycemia and trauma (CHOI, 1988; IKONOMIDOU et 
al., 1989) and with many chronic neurodegenerative 
disorders of the CNS, including Huntington’s and 
Alzheimer’s, and status epilepticus (BREWER, 2000; 
DANBOLT, 2001; MARAGAKIS and ROTHSTEIN, 
2001).
Glu uptake is the process responsible for the main-
tenance of extracellular glutamate concentrations be-
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low neurotoxic levels. This uptake is mainly accompli-
shed by Na-dependent high-afﬁ nity systems media-
ted by a family of proteins known as amino acid trans-
porters (KANNER, 1993; AMARA and FONTANA, 
2002; BEART and O’SHEA, 2007). The different Glu 
transporters subtypes are expressed regionally in dis-
tinct patterns, with glial and neuronal transporter ex-
pression appearing in a coordinated manner during 
CNS development (DANBOLT, 1994, 2001). There are 
5 types of excitatory amino acid transporters (EAAT): 
EAAT1 (GLAST), EAAT2 (GLT-1), EAAT3 (EAAC), EA-
AT4 and EAAT5 (for a review see DANBOLT, 1994 and 
2001). 
In the last decade, Glu transporters and receptors 
dysfunction has been associated with epilepsy, since 
reuptake impediment increases Glu extracellular con-
centration and the consequent neuron population loss 
(for a review see MELDRUM et.al., 1999). In these 
terms, glial cells play a mayor role in the correct main-
tenance of synaptic activity, since this cell type is spe-
cialized in the Glu uptake. Besides, glial cells trans-
form Glu to glutamine (by glutamine synthetase) and 
returns to neurons completing the neurotransmission 
cycle (SCHOUSBOE, 1981). Glu transporters are ex-
pressed in neurons and glial cells. Nevertheless, Glu 
uptake carried out by astrocytes seems to have a mo-
re major role than neurons (MCLENNAN, 1976; RO-
THSTEIN et al., 1996; TANAKA et al., 1997). Glu remo-
val by astrocytes occurs through the Na+ dependent 
transporters GLAST and GLT-1 (HAUGETO et al., 
1996), being the only EAATs expressed by astrocytes 
in mammalian brain, and associating uptake and pro-
tection against neurotoxicity to this cell type. 
Although human studies have not proven a direct 
role of defective Glu uptake in epilepsy, a reduced 
expression of glutamate transporters was found to 
produce or to be associated with seizure activity in 
several animal models. For example, mice lacking the 
astroglial-type GLT-1 develop spontaneous seizures 
(TANAKA et al., 1997), and a decreased expression of 
Glu transporters GLAST, GLT-1, and EAAC1 was found 
in a rat model of absence epilepsy (DUTUIT et al., 
2002). Rothstein et al. previously showed that anti-
sense treatments that knock down expression of 
GLAST, GLT-1, or EAAC1 have differential effects. 
Whereas impairment of the expression of the glial 
subtypes (GLAST and GLT-1) caused massive excito-
toxicity and neurodegeneration, a deﬁ cit in the neuro-
nal subtype (EACC1) was responsible for only mild 
neurotoxicity and epilepsy. 
Moreover, glial cells, although long considered to 
be merely supporting cells in the central nervous sys-
tem, may also have another important role (ZHU and 
HOPER, 2000). Glia performs key buffering functions 
that help to maintain the uptake of potassium and Glu 
and other aspects of the extracellular milieu of neu-
rons. Theoretically, disruption of these glial functions 
could cause neuronal hyperexcitability, since increa-
sed levels of extracellular potassium decrease the 
threshold for neuronal ﬁ ring and increased levels of 
glutamate could increase neuronal activation (CHANG 
and LOWESTEIN, 2003). Thus, a change in the neuro-
nal microenvironment may be another mechanism of 
epileptogenesis.
Recent advances in the technology of live-cell ima-
ging and light-excitation, however, have revealed that 
astrocytes, while lacking membranes that are excita-
ble in classic terms, can generate oscillatory intra-
cellular calcium waves, which can propagate through 
the astrocytic network (CORNELL-BELL et al., 1990) 
and release neuroactive transmitters, such as Glu (BE-
ZZI et al., 1998), even by means of Ca2+- mediated 
exocytosis (BEZZI et al., 2004). It has been shown that 
astrocytic Ca2+ waves propagate via the extrusion of 
ATP into the extracellular space. ATP then acts in a 
paracrine fashion, binding purinergic receptors ex-
pressed on nearby astrocytes (COTRINA et al., 1998; 
GUTHRIE, et al., 1999). Therefore, the development 
of live-cell imaging technology has now revealed the 
existence of the astrocytic “excitable cytoplasm,” si-
milarly to the venerable demonstration of the axonal 
excitable membrane by Hodgkin, Huxley, in the 1930s. 
The discovery of excitable astrocytes begged the 
question of whether these cells could actively drive 
the abnormal neuronal changes underlying epilepsy. 
Indeed, astrocytic calcium waves have properties that 
could facilitate seizures. They can propagate spatially 
and result in long-range changes in excitation of sy-
naptically unconnected neurons (NEWMAN and 
ZAHS, 1998). In addition, astrocytic Ca2+ waves have 
a propagation velocity comparable to that of spreading 
depression, and it was found that Ca2+ waves often 
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precede spreading depression, although a cause–
effect relationship between the two phenomena was 
not demonstrated (KUNKLER and KRAIG, 1998; BA-
SARSKI et al., 1999; MARTINS-FERREIA et al., 
2000).
4. TREATMENT
The primary focus of care for patients with epilep-
sy is the prevention of further seizures, which may, 
after all, lead to morbidity or even mortality (LAU-
TENSCHLAGER et al., 2003).  The goal of treatment 
should be the maintenance of a normal lifestyle, pre-
ferably free of seizures and with minimal side-effects 
of the medication. Up to 70% of people with epilepsy 
could become seizure free with drug treatment. In 
25–30% of people with epilepsy the seizures cannot 
be controlled with drugs. Epilepsy surgery is a safe 
and effective alternative treatment in selected cases 
(WHO, 2006). Attention to the psychosocial, cogniti-
ve, educational and vocational aspects is an important 
part of comprehensive epilepsy care (TOUT, 1999).
Drug therapy is approached to symptom control, 
i.e., suppression of seizures. Therefore drugs used for 
the treatment of epileptic patients should be referred 
to as anticonvulsive drugs and not as antiepileptic dru-
gs, since they do not cure epilepsy. The mechanisms 
of action by which they act are not well understood 
but it involves an alteration of the balance between 
neuronal inhibition and excitation (WHITE, 1999). The-
re are three recognized basic mechanisms of action 
at a cellular level: modulation of voltage-gated ion 
channels (Na+, Ca2+, K+), enhancement of GABA me-
diated inhibitory neurotransmission and attenuation 
of Glu mediated excitatory transmission (KWAN et al., 
2001).
4.1. Voltage-gated ion channels
Voltage-gated ion channels regulate the ﬂ ow of 
ions across cell membranes. Upon depolarization, Na+ 
channels activate leading to ion ﬂ ux into the cell and 
thus propagate the action potential. Then the channel 
enters to an inactivated state. In this state the channel 
cannot re-activate. Repolatization occurs when the 
neuronal membrane can convert the channel back to 
the resting state from which it can re–convert to an 
open state (CATTERALL, 1992; RASDALE and AVOLI, 
1998). Neuronal Na+ channels can cycle through these 
conformational states in only a few milliseconds. This 
process is crucial to maintain normal brain functions 
but at the same time is implicated in generating epi-
leptic discharges. Neuronal Na+ channels are one of 
the most important targets for anticonvulsive drugs 
(UPTON, 1994; MACDONALD and KELLY, 1995; MEL-
DRUM, 1996; WHITE, 1999).
Most of the anticonvulsive drugs used in the tre-
atment of epilepsy bind to the inactivated state of 
sodium channels and thus produce a voltage- and fre-
quency-dependent reduction in channel conductance. 
This in turn limits the repetitive neuronal ﬁ ring but has 
no effect on the generation of single action potentials 
(KWAN et al., 2001).
Voltage–sensitive calcium channels are often re-
cruited in response to initial sodium-dependent action 
potential generation and therefore are also implicated 
in depolarization. Calcium channels can be classiﬁ ed 
into high and low threshold, according to the mem-
brane potential at which they are activated (HOF-
MANN et al., 1994). Several anticonvulsive drugs have 
been reported to target voltage-sensitive Ca2+ chan-
nels in a subtype-specific manner (STEFANI et al., 
1997).
Potassium channels are implicated in excitability 
at a neuronal level. They are involved in the repolariza-
tion of the plasma membranes after Na+ channel acti-
vation (PONGS, 1999) and hence limiting action po-
tential ﬁ ring (PORTER and ROGAWSKI, 1992). Conse-
quently, K+ channel blockers precipitate seizures (YA-
MAGUCHI and ROGAWSKI, 1999), whereas K+ chan-
nel activators have anticonvulsivant effects in some 
experimental seizure models (GANDOLFO et al., 
1989; ROSTOCK et al., 1996).
4. 2. GABA mediated inhibition
GABA is the primary inhibitory neurotransmitter. 
In neurons there are 2 types of GABA receptors; re-
ceptors “A” which open chloride channels and hyper 
polarize cells, and “B” which open K+ and Ca++ chan-
nels. The GABA A receptor has provided an excellent 
target for the development of drugs with an anticon-
vulsant action. Impairment of GABA function is known 
to provoke seizures (LÖSCHER, 1999).  By modifying 
GABA level, one can modify seizure expression. De-
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creased GABA synthesis can lower seizure threshold. 
On the other hand, increasing GABA raises seizure 
threshold. Several anticonvulsive drugs exert their ac-
tion by modulating the GABAergic-system either by 
increasing GABA synthesis, increasing release or 
allosteric receptor facilitation. For example, some dru-
gs elevate brain GABA levels by inhibiting the enzyme 
GABA transaminase, which is responsible for intra-
cellular GABA catabolism. Others, elevate synaptic 
GABA levels by inhibiting the GABA uptake transpor-
ter, GAT1, and prevent the uptake of GABA into neu-
rons and glia. Some of these anticonvulsive drugs act 
by enhancing GABA synthesis and also by decreasing 
neuronal calcium inﬂ ux via a speciﬁ c subunit of volta-
ge-dependent calcium channels. The GABA system 
also represents one of the most successful targets 
for the rational design of new anticonvulsive drugs 
(LÖSCHER, 1998). 
4.3. Glutamate mediated excitatory transmission
Glu is one of the principal excitatory neurotrans-
mitters in the mammalian brain (MELDRUM, 2000). 
However none of the commonly used anticonvulsants 
exerts their pharmacological action by solely modula-
ting the glutamate system. Nevertheless it has been 
reported that blockage of ionotropic glutamate recep-
tors and reduction of Glu release is the way some 
anticonvulsive drugs act although the latter effect may 
be more indicative of their actions on Ca2+ channels 
than a direct effect on the glutamate system (KWAN 
et al., 2001). Furtheremore Hassel et al. showed an 
increase in glutamate transport under chronic valpro-
ate (VPA) treatments in hippocampal preparations 
(HASSEL et al., 2001). Recently, Aguirre et al. deﬁ ned 
GLAST up-regulation by VPA at different levels in Berg-
man glial cells (Aguirre personal comunication). These 
data also highlight the astrocytes key role normal neu-
rotransmission, as well as their potential involvement 
in the etiology or correction of varied epilepsy condi-
tions (ROGAWSKI, 2005).
5. CONCLUDING REMARKS
With the exception of migraine, the epilepsies are 
the most common episodic neurological disorders. 
Epilepsy can be deﬁ ned by a group of disorders that 
leads to recurrent and unpredictable interruptions of 
normal brain function. However, the understanding of 
cellular and molecular bases of human seizure sus-
ceptibility remained unclear. It now appears that some 
forms of idiopathic epilepsy are the result of speciﬁ c 
defects in channel function. The discovery of ion chan-
nel mutations in rare genetic forms of epilepsy, such 
as BFNC, raises the possibility that genetically-deter-
mined alterations in ion channel structure, expression 
or regulation might play a role in susceptibility to the 
more common sporadic epilepsies. The characteriza-
tion of such ion channel alterations, GABAergic and 
Glutamatergic proteins (receptors and transporters) 
regulation with their functional consequences lays the 
basis for the development of targeted, genotype-spe-
ciﬁ c therapies.
Therefore it is not surprising that the current drugs 
used to treat epilepsy have such a diverse range of 
pharmacological actions. Identifying the complete 
and diverse mechanisms by which these drugs act is 
the immediate challenge. Worldwide, the proportion 
of patients with epilepsy who at any given time remain 
untreated is large, and is greater than 80% in most 
low income countries (SANDER, 1991; DREIFUSS, 
1997). The size of this treatment gap reﬂ ects either a 
failure to identify cases or a failure to deliver treat-
ment. In most situations, however, both factors will 
apply. Inadequate case-ﬁ nding and treatment have va-
rious causes, some of which are speciﬁ c to low inco-
me countries. They include people’s attitudes and be-
liefs, government health policies and priorities (or the 
lack of them), treatment costs and drug availability, as 
well as the attitude, knowledge and practice of health 
workers. In addition, there is clear scarcity of epilepsy-
trained health workers in many low income countries. 
The lack of trained personnel and a proper health de-
livery infrastructure are major problems, which contri-
bute to the overall burden of epilepsy (WHO, 2006). 
We believe that one of  the researchers goals 
should be to inform the general public about these di-
sease, and in the future clarify the diferent mechanisms 
that undely this illness and try to ﬁ nd a real cure. Not 
only one that prevents the syntomatology but one that 
can prevent future generations  from this disease.
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